Video Library

Acute myeloid leukemia is a fast-moving cancer that can be fatal in weeks or months without treatment. This presentation reviews the causes, symptoms, and treatments for AML and recent progress in cure rates or prolonged remission for an increasing number of patients.

Genital graft-versus-host-disease can be a lifelong risk for female stem cell or bone marrow transplant recipients. The presentation reviews the symptoms of vaginal and vulvar GVHD and discusses treatments that can restore women to full sexual health and functioning.

The number of stem cell transplants performed is increasing, which means more people are concerned about ongoing complications or late effects after transplant. This presentation reviews potential late effects after a stem cell transplant (hematopoietic cell transplant) using donor cells (aka allogeneic transplant).

Autologous transplants (using the patient’s own cells) are typically done for myeloma or lymphoma. This presentation reviews the potential complications that may arise from this procedure and provides numerous recommendations for how they can be managed or avoided.

Pueden ocurrir problemas cardiovasculares después de un trasplante de células madre. Conozca cuáles son comunes y qué puede hacer para reducir el riesgo de desarrollar problemas cardíacos y vasculares.

Ocular graft-versus-host-disease occurs in 40% to 60% of allogeneic transplant patients. Early detection and treatment are important. This presentation reviews the most common symptoms and effective remedies for ocular GVHD.

CAR T-cell therapy is a new treatment option for patients with acute lymphoblastic leukemia, some lymphomas, and multiple myeloma that have not responded to prior therapies. This presentation describes how CAR T-cell therapy works, its risks and side effects, and how these may be effectively managed.

Caregivers for stem cell transplant recipients deal with a lot of responsibility and uncertainty. Many find their role very stressful and burnout is common. Practicing self-care helps caregivers maintain both their physical and emotional health. Many thanks to Takeda Pharmaceutical Company whose support, in part, made this presentation possible.

Half of patients who have a stem cell transplant using donor cells (an allogeneic transplant) develop chronic graft-versus-host-disease (GVHD). In up to a third of those patients, GVHD affects the mouth, esophagus, stomach and/or GI tract. GVHD can also affect the liver and/or pancreas. This presentation describes the symptoms and treatment options for GI and liver GVHD.

Fatigue is the most common symptom associated with cancer treatment and it is caused by many factors. This presentation discusses factors that contribute to fatigue, and how an individualized exercise program can be an effective strategy to fight fatigue.

Patients who have had a stem cell transplant have a higher risk of developing a second cancer than the general population. The risk of developing a second cancers increases over time. Life-long surveillance and testing is important to catch any second cancer early, when treatment is most effective.

Presenters: Mohamed Hegazi MD, UofL Brown Cancer Center Gerhard Hildebrandt MD, University of Kentucky Blood and Marrow Transplantation and Cellular Therapy Program Navneet Majhail MD, MS, FASTCT, Sarah Cannon Transplant and Cellular Therapy Program at TriStar Centennial